ProShares UltraShort NASDAQ Biotechnology

BIS

Valor de mercado US$ 2 mi

Central banks will remain at the heart of managing future financial crises, but rising public debt and other key changes could make their task more difficult and controversial, the head of the ​Bank for International Settlements (BIS) said on Monday.

Although some deem it blasphemous to suggest the AI boom is another bubble, the world's central banking forum and watchdog has warned against getting swept up in the frenzy, just as investors appear increasingly reluctant to second-guess it.

Global pressures from rising public debt to financial fragilities and the sustainability of ​the AI boom are increasing risks, underscoring the need for disciplined policymaking, according to the Bank for International ‌Settlements.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.